Biologics Exclusivity Will Be Less Then 10 Years, Teva’s Marth Vows
Executive Summary
Any legislation creating a pathway for approving follow-on biologics will need to include a brand exclusivity period of less than 10 years, Teva North America CEO William Marth maintains
You may also be interested in...
Will Waxman Offer Seven Years Of Exclusivity For Follow-On Biologics?
Revised bill is expected shortly as Reps. Eshoo and Barton draw battle line against the Commerce Committee chairman.
GOP Players In Health Debate: McCain To HELP; Enzi Adds Finance To Resume
In the face of substantially higher Democratic congressional majorities, two Republican senators have ensured their place in the debate over health care reform and providing Americans with access to safe medicines